Advertisement
Advertisement
ACAD
Acadia Pharmaceuticals Inc.
20.47
USDSponsored
-0.12
-0.58%
Nov 02, 15:59 UTC -5
Closed
After-Market
20.47
0.00
0.00%
Acadia Pharmaceuticals Inc. (ACAD) Earnings
ACAD Earnings Reports
Positive Surprise Ratio
ACAD beat 28 of 43 last estimates.
65%
Next Report
In 2 Days
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$339.12M
/$0.20
Implied change from Q2 26 (Revenue/ EPS)
+10.12%
/+11.11%
Implied change from Q3 25 (Revenue/ EPS)
+21.71%
/-52.38%
Acadia Pharmaceuticals Inc. earnings per share and revenue
On Aug 04, 2026, ACAD reported earnings of 0.18 USD per share (EPS) for Q2 26, beating the estimate of 0.05 USD, resulting in a 207.17% surprise. Revenue reached 307.96 million, compared to an expected 301.77 million, with a 2.05% difference. The market reacted with a +6.08% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of 0.20 USD, with revenue projected to reach 339.12 million USD, implying an increase of 11.11% EPS, and increase of 10.12% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Krystal Biotech, Inc. Common Stock
Report Date
Nov 02, 2026 For Q3 26
Estimate
$1.80
Actual
$2.04
Surprise
+13.48%
Axsome Therapeutics, Inc
Report Date
Nov 02, 2026 For Q3 26
Estimate
-$0.59
Actual
-$0.25
Surprise
+58.25%
Travere Therapeutics, Inc. Common Stock
Report Date
Nov 02, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.55
Surprise
-846.64%
Recursion Pharmaceuticals, Inc. Class A Common Stock
Report Date
Nov 02, 2026 For Q3 26
Estimate
-$0.23
Actual
-$0.22
Surprise
+5.54%
AstraZeneca PLC
Report Date
Oct 30, 2026 For Q3 26
Estimate
$2.66
Actual
$2.79
Surprise
+4.56%
Vertex Pharmaceuticals Inc
Report Date
Nov 02, 2026 For Q3 26
Estimate
$4.88
Actual
$4.76
Surprise
-2.51%
Regeneron Pharmaceuticals Inc
Report Date
Oct 30, 2026 For Q3 26
Estimate
$16.56
Actual
$20.07
Surprise
+21.18%
Jazz Pharmaceuticals, Inc.
Report Date
Nov 02, 2026 For Q3 26
Estimate
-$3.93
Actual
-$3.88
Surprise
+1.38%
BioMarin Pharmaceuticals Inc
Report Date
Nov 02, 2026 For Q3 26
Estimate
$0.12
Actual
$0.23
Surprise
+89.77%
Vor Biopharma Inc. Common Stock
Report Date
Oct 30, 2026 For Q3 26
Estimate
-$0.83
Actual
-$1.45
Surprise
-74.07%
FAQ
What were Acadia Pharmaceuticals Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Acadia Pharmaceuticals Inc. reported EPS of $0.18, beating estimates by 207.17%, and revenue of $307.96M, 2.05% above expectations.
How did the market react to Acadia Pharmaceuticals Inc.'s Q2 2026 earnings?
The stock price moved up 6.08%, changed from $27.15 before the earnings release to $28.80 the day after.
When is Acadia Pharmaceuticals Inc. expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Acadia Pharmaceuticals Inc.'s next earnings report?
Based on 7
analysts, Acadia Pharmaceuticals Inc. is expected to report EPS of $0.20 and revenue of $339.12M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.